

Mutations in the PPE Genes that Confer Resistance to a Nitroimidazopyran Drug on *Mycobacterium bovis* Strains

Young-Min Bae* and Lacy Daniels

Department of Microbiology, University of Iowa, Iowa City, Iowa 52242, USA

Received January 19, 2005 / Accepted February 24, 2005

We used the IS1096 transposon to construct *Mycobacterium bovis* BCG mutants resistant to an anti-tuberculosis drug PA-824 and isolated several different mutants. We identified the locations of the insertions and found that the insertions were at various sites including the genes for the PPE proteins. HPLC analyses of the extracts of these five PPE mutant cells showed that three mutants produced only F0, an intermediate for the synthetic pathway of coenzyme F₄₂₀, and the remaining two neither F0 nor F₄₂₀. These data suggest that the products of these PPE genes are somehow involved in the biosynthesis of the coenzyme F₄₂₀.

Key words – *Mycobacterium bovis*, transposon mutagenesis, PPE mutants, coenzyme F₄₂₀

The genus *Mycobacterium* includes many species pathogenic to humans and animals. *Mycobacterium bovis* is a member of the *M. tuberculosis* complex and remarkably similar to *M. tuberculosis*, the important agent of human tuberculosis, with regard to nucleotide sequence of the chromosomal DNA, cell physiology and pathogenicity[9]. *M. bovis* also causes tuberculosis in humans and animals.

Coenzyme F₄₂₀ is produced by both *M. tuberculosis* and *M. bovis*, and is required for activation of the experimental anti-tuberculosis drug PA-824 by these bacteria[18]. F₄₂₀ functions as an electron carrier (Fig. 1) and is used by F₄₂₀-dependent glucose-6-phosphate dehydrogenase in both strains. Therefore, both strains incapable of producing F₄₂₀ are resistant to this drug at the concentration of 5 mg/ml. *M. bovis* and *M. tuberculosis* produce coenzyme F₄₂₀ and an intermediate, F0. It is thought that F₄₂₀-dependent reactions might be important for these pathogens. If it is true, specific enzymatic steps for the biosynthesis of F₄₂₀ could be targets for chemotherapy.

We constructed a mutant library of *M. bovis* BCG by using a mycobacterial transposon and isolated several different mutants resistant to PA-824. The insertion sites were identified and their DNA sequence was analyzed. We found that five of those mutants had insertions in the PPE genes. Three of the mutants produced only F0. Neither F0 nor F₄₂₀ was detected in the remaining two. The PPE gene family, together with the PE family, comprise approximately 10% of the coding

capacity of the *M. tuberculosis* genome[7]. Although the role of the majority of PE and PPE proteins are unknown, there is some evidence that these proteins might be exposed to the cell surface and involved in antigenic variation[17]. We, in this article, report that five of the PPE proteins are involved in the synthesis of the coenzyme F₄₂₀, indicating that PPE proteins have enzymatic functions.

MATERIALS AND METHODS

Bacterial strains, plasmids and media.

M. bovis BCG Montreal strain and the plasmid pPR29 were described elsewhere[4,15]. *M. bovis* BCG cells were routinely grown in Middlebrook 7H9 medium (Difco Laboratories, Detroit, MI) supplemented with 0.2% glycerol, 0.005% Tween-80 and 10% ADC enrichment.

Electrotransformation of *M. bovis* BCG cells.

M. bovis BCG cells were electrotransformed with pPR29 as described[15]. The transformed cells were plated on the Middlebrook 7H9 agar containing kanamycin (30 mg/ml) and gentamycin (5 mg/ml), and incubated at 32°C for 3 weeks. A colony was picked from the transformed cells, streaked on the same selection agar, and incubated for another 3 weeks. *M. bovis* BCG cells not transformed with pPR29 were always streaked parallel to the transformants as a negative control.

Selection of the transposon-induced mutants resistant to PA-824.

M. bovis BCG cells transformed by pPR29 were grown in

*Corresponding author

Tel : +82-55-279-7463, Fax : +82-55-279-7460

E-mail : yominbae@sarim.changwon.ac.kr

Present address : Department of Microbiology, Changwon University, Changwon Kyungnam 641-773, Korea




Fig. 1. The structure of the coenzyme F_{420} . The oxidized form is shown on the left and the reduced form is shown on the right.

7H9 liquid medium and plated on the 7H9 agar plates with PA-824 (5 mg/ml), kanamycin (20 mg/ml), sucrose (2% w/v), riboflavin (0.05 mg/ml) and cyanocobalamin (0.2 mg/ml) at the cell density of 2.4×10^5 CFU/plate. After incubation at 39°C for 3 weeks, we picked several colonies and streaked on the same selection agar, and incubated for another 3 weeks.

Inverse PCR and DNA sequence determination.

The chromosomal DNA of the mutants was prepared[11], cleaved with *EagI*, self-ligated and used for inverse PCR (Choi *et al.* 2001). The PCR primers used were 5'-GTACGTCACCGT-CATCATCG-3' and 5'-GAGTCACGCTGTCACGTACA-3', and both are complementary to the *IS1096* DNA. The PCR products were purified by the QIAquick PCR purification kit (QIAGEN Inc., Valencia, CA) and the DNA sequence was determined at the University of Iowa DNA facility. The DNA sequence was analyzed by the BLAST program.

HPLC analysis.

Thirty milliliters of culture of each mutant was centrifuged and resuspended in 1 ml of distilled water. The cells were then incubated at 100°C for 15 minutes, centrifuged, and the supernatant was separated with Beckman System Gold 126 Solvent Module HPLC in the 300 mm \times 3.9 mm C18 column from Spelco Inc. at the elution rate of 1 ml/min. Buffer A was 27.5 mM sodium acetate (pH 4.7) containing 2% acetonitrile; buffer B was 100% acetonitrile. The portion of buffer B in the elution buffer was varied as follows: 0 to 2 min, 0%; 2 to 6 min, 0 to 2% (linear gradient); 6 to 15 min, 2 to 10%; 15 to 22 min, 28%; 22 to 27 min, 28 to 0%. The separated fraction was analyzed with System Gold 168 detector (Beckman Co.) and RF-10AXL fluorescence detector (Shimadzu Co.).

RESULTS

Construction of the *M. bovis* BCG insertional mutant library.

A mycobacterial transposon, *IS1096*, transposes at a frequency of 7.2×10^5 per cell in a random fashion[6]. The plasmid, pPR29, carrying *IS1096* was used to introduce insertional mutations to the *M. bovis* BCG strain. This plasmid carries a temperature-sensitive mycobacterial replication origin, a copy of the *Bacillus subtilis sacB* gene, and the resistance marker for gentamycin[14,15]. The transposon on the pPR29 carries a kanamycin marker on itself. The temperature-sensitive replication origin functions at 32°C but not at 39°C. The cells carrying the *sacB* gene are sensitive to 10% sucrose. BCG cells transformed with these plasmids were selected for resistance to kanamycin and sucrose to select for the cells carrying the transposon inserted in the chromosome but have lost the plasmid. Tens of colonies appeared under these selective conditions and several of them were analyzed further.

Identification of the transposon-inserted locations.

The cells of the insertional mutant library were subject to selection for resistance to PA-824. The chromosomal DNA was prepared from these cells and inverse PCR was performed to identify the insertion site of the *IS1096* for each mutant. We obtained five different insertional PPE mutants and these were designated YMBG34, 36, 45, 47 and 51, respectively.

Analysis of the mutants for the production of F_{420} and F0.

The mutant cells were grown in liquid medium and their extract was analyzed by an HPLC. The *M. bovis* BCG wild

type extract showed distinct peaks for the F₄₂₀ and F₀, but the extract of the mutant cells showed various results (Table 1). Three mutants produced only F₀ and showed higher peak for F₀ than the wild type extract indicating the accumulation of F₀. The remaining two mutants produced neither F₄₂₀ nor F₀.

DISCUSSION

Coenzyme F₄₂₀ is a 7,8-dimethyl-8-hydroxyl 5-deazaflavin and transfers electrons. It has been reported to be present in methanogens, mycobacteria, *Nocardia*, *Streptomyces*, a green alga *Scenedesmus*, a cyanobacteria *Synechocystis* and an halophilic archeon *Halobacterium*[4]. Although F₄₂₀ is present among several organisms, there are minor differences in its structure and roles.

The biosynthetic pathway of the F₄₂₀ is not understood clearly, but a hypothetical pathway had been proposed[8,12,16]. F₄₂₀ is synthesized from F₀ in accordance with their model. In this study, we isolated mutants producing only F₀, but mutants producing only F₄₂₀ were not isolated. This result coincides with their model.

Interestingly, mutants YMBCG34, 36, 45, 47 and 51 have the insertion in the PPE genes. There are 99 PE genes and 68 PPE genes in the *M. tuberculosis* genome[2,7,19]. The product of these genes are peculiar proteins having conserved N-terminal sequence and variable C-terminus which is very rich for specific amino acids. The names PE and PPE are derived from the motifs Pro-Glu (PE) and Pro-Pro-Glu (PPE) found near the N-terminus of these proteins. Because of unknown function, it is now suggested that at least some of the PE and PPE proteins are surface proteins and play a role in adhesion and immune modulation[2,3,5,13,17]. Voskuil *et al.* reported that the synthesis of many PE and PPE proteins are regulated differentially[20]. There has been no evidence reported for the enzymatic activities of the PE or PPE proteins yet. We, in this article, report for the first time that the insertional mutants in the PPE genes have lost the ability to produce the coenzyme F₄₂₀. Our data clearly suggest that at least some PPE genes encode products carrying enzymatic activities.

There is an interesting feature observed in the Table 2. The two smaller proteins, Rv2608 and Rv0096 have alanine as the most abundant amino acid and leucine as the second abundant. But, the other three larger proteins have glycine as the most abundant and asparagine as the second most abundant. Tekaiia *et al.* reported the most abundant amino acid from the whole genome of the *M. tuberculosis* is alanine and the second is glycine[19]. Alanine and glycine comprises 13.2% and 10%, respectively. PPE proteins in the Table 2 have alanine

Table 1. Genes mutated by a transposon insertion and the profile of the F₄₂₀ and F₀ production

Mutant	F ₄₂₀	F ₀	Inserted gene
YMBCG34	-	-	Rv2608
YMBCG36	-	+	Rv0096
YMBCG45	-	+	Rv1917c
YMBCG47	-	+	Rv0355c
YMBCG51	-	+	Rv0305c

Table 2. Predicted molecular weight of the mutated PPE proteins and their abundant amino acids

Gene	Molecular weight (kD)	Most ^a	Second most ^b
Rv2608	60	A (15%)	L (12%)
Rv0096	47	A (21%)	L (11%)
Rv1917c	143	G (20%)	N (11%)
Rv0355c	327	G (21%)	N (16%)
Rv0305c	99	G (17%)	N (11%)

^aThe most abundant amino acid

^bThe second most abundant amino acid

or glycine as the most abundant amino acids although their percentage is higher than the whole cellular percentage. Asparagine comprises only 2.5% for the whole *M. tuberculosis* cell, but the three large proteins in the Table 2 have much higher percentage of asparagines. Tekaiia *et al.* suggested that asparagine storage could be a possible function for the PPE proteins[19]. If that is true, Rv1917c, Rv0355c and Rv0305c appear to be dual function proteins: the first enzymes involved in biosynthesis of F₄₂₀ and the second storage sites for asparagine. Sampson *et al.* expressed the Rv1917c protein in *M. smegmatis* and *M. bovis* BCG and found that this protein is surface exposed[17].

Another intriguing feature is the unusually large size of the Rv0355c. This protein consists of 3,300 amino acids and the calculated molecular weight is 327 kD. We think this protein might be spliced after translation or its mRNA spliced before translation. Evidence is now accumulating for the protein splicing in prokaryotes[1].

ACKNOWLEDGEMENTS

This work was supported by National Institutes of Health grant GM56177 and U.S. Department of Agriculture grant 4132008 to L.D.

REFERENCES

1. Amitai, G., O. Belenkiy, B. Dassa, A. Shainskaya and S. Piekrovski. 2003. Distribution and function of new bacterial

- intein-like protein domains. *Mol. Microbiol.* **47**, 61-73.
2. Banu, S., N. Honore, B. Saint-Joanis, D. Philpott, M. Prevost and S. Cole. 2002. Are the PE-PGRS proteins of *Mycobacterium tuberculosis* variable surface antigens? *Mol. Microbiol.* **44**, 9-19.
 3. Brennan, M. J., G. Delogu, Y. Chen, S. Bardarov, J. Kriakov, M. Alavi and W. R. Jacobs, Jr. 2001. Evidence that mycobacterial PE-PGRS proteins are cell surface constituents that influence interactions with other cells. *Infect. Immun.* **69**, 7326-33.
 4. Choi, K-P., T. B. Bair, Y.-M. Bae and L. Daniels. 2001. Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for *fbtA* and *fbtB* in coenzyme F₄₂₀ biosynthesis by *Mycobacterium bovis* BCG. *J. Bacteriol.* **183**, 7058-7066.
 5. Choudhary, R. K., S. Mukhopadhyay, P. Chakhaiyar, N. Sharma, K. J. R. Murthy, V. M. Katoch and S. E. Hasnain. 2003. PPE antigen Rv2430c of *Mycobacterium tuberculosis* induces a strong B-cell response. *Infect. Immun.* **71**, 6338-6343.
 6. Cirillo, J. D., R. G. Barletta, B. R. Bloom and W. R. Jacobs, Jr. 1991. A novel transposon trap for Mycobacteria: isolation and characterization of IS1096. *J. Bacteriol.* **173**, 7772-7780.
 7. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krough, J. McLean, S. Moule, L. Murphy, S. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, S. Skelton, S. Squares, R. Squares, J. E. Sulston, K. Taylor, S. Whitehead and B. G. Barrell. 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393**, 537-544.
 8. Eisenreich, W. B., B. Schwarzkopf and A. Bacher. 1991. Biosynthesis of nucleotides, flavins, and deazaflavins in *Methanobacterium thermoautotrophicum*. *J. Biol. Chem.* **266**, 9622-9631.
 9. Garnier, T., K. Eiglmeier, J. Camus, N. Medina, H. Mansoor, M. Pryor, S. Duthoy, S. Grondin, C. Lacroix, C. Monsempe, S. Simon, B. Harris, R. Atkin, J. Doggett, R. Mayes, L. Keating, P. R. Wheeler, J. Parkhill, B. G. Barrell, S. T. Cole, S. V. Gordon and R. G. Hewinson. 2003. The complete genome sequence of *Mycobacterium bovis*. *Proc. Natl. Acad. Sci. USA* **100**, 7877-7882.
 10. Hall, M. F., C. J. Noren, F. B. Perler and I. Schildkraut. 2002. Creation of an artificial bifunctional intein by grafting a homing endonuclease into a mini-intein. *J. Mol. Biol.* **323**, 173-179.
 11. Husson, R. N., B. E. James and R. A. Young. 1990. Gene replacement and expression of foreign DNA in mycobacteria. *J. Bacteriol.* **172**, 519-524.
 12. Jaenchen, R., P. Schonheit and R. K. Thauer. 1984. Studies on the biosynthesis of coenzyme F₄₂₀ in methanogenic archaea. *Arch. Microbiol.* **137**, 362-365.
 13. Okkels, L. M., I. Brock, F. Follman, E. M. Agger, S. M. Arend, T. H. M. Ottenhoff, F. Oftung, I. Rosenkrands and P. Andersen. 2003. PPE protein (Rv3873) from DNA segment RD1 of *Mycobacterium tuberculosis*: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. *Infect. Immun.* **71**, 6116-6123.
 14. Pelicic, V., J. Reytrat and B. Gicquel. 1996. Expression of the *Bacillus subtilis sacB* gene confers sucrose sensitivity on Mycobacteria. *J. Bacteriol.* **178**, 1197-1199.
 15. Pelicic, V., M. Jackson, J. M. Reytrat W. R. Jacobs, Jr., B. Gicquel, and C. Guilhot. 1997. Efficient allelic exchange and transposon insertion mutagenesis in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* **94**, 10955-10960.
 16. Reuke, B., S. Korn, W. Eisenreich and A. Bacher. 1992. Biosynthetic precursors of deazaflavins. *J. Bacteriol.* **174**, 4042-4049.
 17. Sampson, S. L., P. Lukey, R. M. Warren, P. D. van Helden, M. Richardson and M. J. Everett. 2001. Expression, characterization and subcellular localization of the *Mycobacterium tuberculosis* PPE gene Rv1917c. *Tuberculosis* **81**, 305-317.
 18. Stover, C. K., P. Warrener, D. R. Van Devanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Anderson, J. A. Towell, T. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* **405**, 962-966.
 19. Tekaia, F., S. V. Gordon, T. Garnier, R. Brosch, B. G. Barrell and S. T. Cole. 1999. Analysis of the proteome of *Mycobacterium tuberculosis* in silico. *Tubercle Lung Disease* **79**, 329-342.
 20. Voskuil, M. I., T. Schnappinger, R. Rutherford, Y. Liu and G. K. Schoolnik. 2004. Regulation of the *Mycobacterium tuberculosis* PE/PPE genes. *Tuberculosis* **84**, 256-262.

초록 : *Mycobacterium bovis* 균주들이 nitroimidazopyran 항생제에 내성을 갖게 해주는 PPE 유전자들의 돌연변이들

배영민* · Lacy Daniels
(Iowa 대학교 미생물학과)

IS1096 transposon을 사용하여 결핵균에 작용하는 항생제인 PA-824에 내성을 나타내는 *Mycobacterium bovis* BCG의 돌연변이 균주를 얻고자 하였고, 그 결과 24 종류의 서로 다른 돌연변이 균주를 얻을 수 있었다. Transposon이 insertion된 부위를 알아내기 위해서 각각의 돌연변이 균주로 inverse PCR을 수행하였고, PPE 유전자를 포함한 여러 가지 부위에 insertion된 transposon의 위치를 확인할 수 있었다. PPE 유전자에 insertion 돌연변이가 발생한 5개 균주의 세포 추출물을 HPLC로 분석한 결과, 3개에서는 야생균주에서 관찰되는 coenzyme F₄₂₀이 존재하지 않았고, 그 생합성 경로의 중간산물인 F0만 존재하였다. 또한 나머지 2개에서는 F0 또는 F₄₂₀ 어느 것도 존재하지 않았다. 이 결과는 PPE 유전자들의 산물들이 coenzyme F₄₂₀에 어떤 식으로든 관여하고 있음을 나타낸다고 할 수 있다.